Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation
| Autor: | Masaru Hagiwara, Chimori Konaka, Keishi Otani, Takefumi Oikawa, Tatsuo Ohira, Norihiko Ikeda |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Cancer Research
Pathology medicine.medical_specialty biology business.industry Point mutation Cancer Articles Gene mutation medicine.disease respiratory tract diseases T790M Exon Gefitinib Oncology medicine Cancer research biology.protein Epidermal growth factor receptor Lung cancer business medicine.drug |
| Zdroj: | Molecular and Clinical Oncology. 3:329-333 |
| ISSN: | 2049-9469 2049-9450 |
| DOI: | 10.3892/mco.2014.455 |
| Popis: | The aim of this study was to investigate whether the pattern of epidermal growth factor receptor (EGFR) gene mutations affects sensitivity to gefitinib treatment. We investigated 44 surgically resected non-small-cell lung cancer (NSCLC) specimens obtained between 2001 and 2012 at the Tokyo Medical University Hospital. The specimens were obtained from patients treated with gefitinib as 1st-, 2nd-, or 3rd-line therapy for postoperative recurrent NSCLC. We detected EGFR mutations using the cycleave PCR technique. In addition, the specimens from non-responders were stained with antibodies against hepatocyte growth factor receptor (HGFR; MET) and hepatocyte growth factor (HGF). We assessed the progression of non-responders over a period of 2 months. Intermediate responders were considered to be patients who responded (exhibiting at least stable disease) to gefitinib therapy for 3–11 months, while long-term responders were defined as those who responded to gefitinib therapy for >12 months. The NSCLCs were histologically classified as 43 adenocarcinomas and one large-cell neuroendocrine carcinoma. One patient had an exon 18 point mutation, 23 an exon 19 deletion, 2 an exon 20 point mutation, 16 an exon 21 point mutation and 2 patients had both exon 20 and 21 point mutations. There were 4 non-responders, including the 2 patients with exon 20 mutation, 25 intermediate responders (including 10 patients under ongoing treatment) and 15 long-term responders (2 of whom are under ongoing treatment), including the 2 patients with both exon 20 and 21 mutations. Of the specimens obtained from non-responders, 3 stained with the anti- MET antibody and 1 stained with the anti-HGF antibody. Therefore, NSCLC with exon 20 mutation may respond to gefitinib treatment in the presence of an additional EGFR mutation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|